🇺🇸 FDA
Pipeline program

Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)

17508

Approved small_molecule completed

Quick answer

Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321) for Macular Degeneration is a Approved program (small_molecule) at Regeneron UK Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Regeneron UK Limited
Indication
Macular Degeneration
Phase
Approved
Modality
small_molecule
Status
completed

Clinical trials